Hydromorph Contin 24mg 12h-capsule Canada

Description

### HYDROMORPH CONTIN 24MG 12H-CAPSULE CANADA

### UNDERSTANDING HYDROMORPHONE HYDROCHLORIDE AND CONTROLLED-RELEASE FORMULATION IN HYDROMORPH CONTIN 24MG

Hydromorphone hydrochloride is a potent semi-synthetic opioid agonist derived from morphine. It primarily binds to mu-opioid receptors in the central nervous system, altering the perception of and emotional response to pain. Unlike immediate-release formulations, Hydromorph Contin is a **controlled-release capsule** designed to release hydromorphone slowly over a **12-hour period** . This makes it suitable for around-the-clock pain management in patients requiring continuous, long-term opioid therapy.

Health Canada approves Hydromorph Contin exclusively for adults when non-opioid analgesics or weaker opioids do not provide sufficient relief. Due to the greater risks of overdose and death with controlled-release opioid formulations, it should only be used when alternative treatment options are ineffective, not tolerated, or inadequate . The product monograph includes a Canadian Specific Opioid targeted Risk Management Plan (CSO-tRMP) .

### INDICATIONS FOR USE OF HYDROMORPH CONTIN 24MG IN CANADIAN PRACTICE

Hydromorph Contin 24mg 12h-capsule is indicated for the management of moderate to severe pain in adults requiring continuous, around-the-clock opioid therapy for an extended period . In Canadian healthcare settings, it may be prescribed in contexts such as:

– Chronic cancer-related pain or palliative care under the supervision of specialists through provincial cancer agencies or palliative programs.
– Severe chronic non-cancer pain when non-opioid and non-pharmacologic options have been optimized and found insufficient.
– Long-term pain management for conditions such as severe osteoarthritis, chronic back pain, or neuropathic pain.

**Limitations of Use:**
Because of the risks of addiction, abuse, and misuse, and because of the greater risks of overdose and death with controlled-release opioid formulations, Hydromorph Contin should only be used in patients for whom alternative treatment options are ineffective, not tolerated, or inadequate .

**Important:** Hydromorph Contin is **not indicated** for:
– As-needed (PRN) analgesic use
– Acute pain management, including outpatient or day surgeries
– Peri-operative pain management
– Mild, intermittent, or short-duration pain that can be managed with other pain medications

Health Canada has not authorized its use in pediatrics . In geriatric patients, initiation requires lower starting doses with slow titration due to greater frequency of decreased hepatic, renal, or cardiac function .

### CONTRAINDICATIONS FOR HYDROMORPH CONTIN 24MG CANADA

Strict contraindications exist to protect patient safety :

– Hypersensitivity to hydromorphone, other opioids, or any ingredient in the formulation.
– Known or suspected mechanical gastrointestinal obstruction (e.g., bowel obstruction or strictures) or any diseases/conditions that affect bowel transit (e.g., ileus of any type).
– Suspected surgical abdomen (e.g., acute appendicitis or pancreatitis).
– Mild, intermittent, or short-duration pain that can be managed with other pain medications.
– Acute pain management, including use in outpatient or day surgeries.
– Peri-operative pain management.
– Acute or severe bronchial asthma, chronic obstructive airway, or status asthmaticus.
– Acute respiratory depression, elevated carbon dioxide (CO2) levels in the blood, and cor pulmonale.
– Acute alcoholism, delirium tremens, and convulsive disorders .
– Severe CNS depression, increased cerebrospinal or intracranial pressure, and head injury.
– Concurrent or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs) .
– Women who are pregnant, during labour and delivery, or breastfeeding .

### SERIOUS WARNINGS AND PRECAUTIONS FOR HYDROMORPH CONTIN 24MG

Health Canada’s product monograph highlights a prominent Serious Warnings and Precautions Box :

– **Addiction, Abuse, and Misuse:** Hydromorph Contin poses risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Each patient’s risk should be assessed prior to prescribing, and all patients should be monitored regularly .
– **Life-Threatening Respiratory Depression:** Serious, life-threatening, or fatal respiratory depression may occur with use. Risk is highest during initiation or dose escalation. Patients should be monitored for respiratory depression .
– **Accidental Exposure:** Accidental ingestion of even one dose, especially by children, can result in a fatal overdose .
– **Neonatal Opioid Withdrawal Syndrome:** Infants exposed in-utero or through breast milk are at risk of life-threatening respiratory depression upon delivery or when nursed. Prolonged use in pregnancy can lead to severe withdrawal in newborns .
– **Interactions with Alcohol and CNS Depressants:** Combining with alcohol, benzodiazepines, or other sedatives greatly increases the risk of additive drowsiness and reduced breathing, which can be dangerous and possibly life-threatening .
– **Administration Instructions:** Swallow capsules whole with a full glass of water or sprinkle contents on applesauce or custard and swallow immediately without chewing . **Do not cut, break, chew, dissolve, or crush the capsule or its contents**, as this can lead to rapid release and absorption of a potentially fatal dose of hydromorphone .

Canadian patients are encouraged to access take-home naloxone through provincial harm reduction programs.

### DOSAGE AND ADMINISTRATION OF HYDROMORPH CONTIN 24MG CANADA

Dosing is highly individualized based on pain severity, prior opioid exposure, age, weight, and organ function. The 24 mg strength is typically used for patients who have developed tolerance or require higher amounts under close supervision. **Do not take a single dose greater than 12 mg every 12 hours unless you are “opioid tolerant”** – your doctor will determine this .

**How to Take Hydromorph Contin 24mg :**

– **Swallowed Whole:** Swallow the capsule whole with a full glass of water. Do not cut, break, chew, dissolve, or crush the capsule – this can be dangerous and life-threatening.
– **Sprinkled:** Open the capsule and sprinkle the entire contents onto a tablespoon of applesauce or custard. Swallow immediately without chewing. Rinse your mouth and swallow the water. Do not keep any of the mixture for another dose.

**Dosing Schedule:**
– Take every 12 hours .
– Take regularly and continuously to maintain its beneficial effects .
– For acute pain, Health Canada recommends limiting use to a maximum of 7 days at the lowest effective dose. In chronic non-cancer pain, guidelines advise against exceeding 90 morphine milligram equivalents daily without thorough reassessment.

**Special Populations:**
– **Elderly patients:** Start at the lowest dose and titrate slowly .
– **Hepatic or renal impairment:** Significant dose reduction recommended .
– **Respiratory conditions:** Dose selection should be cautious .

Prescriptions for narcotics are often quantity- and duration-limited, with monitoring via provincial drug monitoring programs.

### COMMON AND SERIOUS SIDE EFFECTS OF HYDROMORPH CONTIN 24MG

**Very common side effects** include constipation, nausea, vomiting, drowsiness, dizziness, and sedation . Constipation is common – to prevent it, drink plenty of water or juice and eat more dietary fibre . Other frequent effects may include dry mouth, headache, itching, sweating, and fatigue .

**Serious reactions** that require immediate medical attention or reporting to Health Canada’s Canada Vigilance Program include :

– Respiratory depression: slow, shallow, or weak breathing.
– Severe hypotension.
– Serotonin syndrome: a rare but potentially life-threatening condition with symptoms including fever, sweating, shivering, diarrhea, nausea, vomiting, muscle shakes or stiffness, fast heartbeat, confusion, agitation, restlessness, or hallucinations. Risk increases if taking certain antidepressants or migraine medications .
– Adrenal insufficiency: symptoms include nausea, vomiting, feeling tired, weak, or dizzy, and decreased appetite. Risk increases with opioid use longer than one month .
– Opioid-induced hyperalgesia: paradoxical increase in pain.
– Allergic reactions or seizures.
– Withdrawal symptoms: body aches, diarrhea, nausea, nervousness, restlessness, goose bumps, shaking, shivering, stomach cramps, fast heart rate, fever, sweating may occur if stopped suddenly .

Patients should promptly report any concerning symptoms to their healthcare team.

### DRUG INTERACTIONS WITH HYDROMORPH CONTIN 24MG CANADA

Significant interactions can occur with :

– **Alcohol** – Do not drink alcohol while taking this medication. It can lead to unusually slow or weak breathing, serious side effects, or fatal overdose .
– **Other CNS depressants** – Benzodiazepines, sleeping pills, anxiety medications, antidepressants, sedatives, muscle relaxants, and antihistamines can cause additive drowsiness and reduced breathing which can be life-threatening .
– **Serotonergic medications** – Certain antidepressants (SSRIs, SNRIs, MAOIs, tricyclic antidepressants) and migraine treatments (triptans) increase risk of serotonin syndrome .
– **Monoamine oxidase inhibitors** – Do not take with MAO inhibitors or if you have taken them in the last 14 days .
– **Anticholinergic drugs** – Increased risk of severe constipation or urinary retention.
– **Other medications** – St. John’s Wort, anticoagulants, some heart medications .

Canadian pharmacists routinely screen for interactions using provincial drug information systems. Patients must disclose all medications, herbal products, and substances they use.

### LEGAL ACCESS AND PRESCRIBING OF HYDROMORPH CONTIN IN CANADA

Hydromorph Contin is a controlled substance and can only be obtained with a valid prescription from a licensed Canadian prescriber. It is dispensed at licensed pharmacies across the country.

**Veterans Affairs Canada:**
This medication is available Canada-wide but requires Special Authorization. It is not a Standard Benefit .

**Provincial Drug Plans:**
Provincial drug benefit plans (e.g., PharmaCare in British Columbia, Ontario Drug Benefit, RAMQ in Quebec) may offer coverage under specific criteria or exceptional access programs. When travelling within Canada or internationally, patients must comply with federal regulations for controlled substances and carry proper documentation.

### CANADA’S OPIOID CRISIS AND RESPONSIBLE HYDROMORPH CONTIN USE

Canada has experienced significant opioid-related harms. While some regions have seen declines due to harm reduction efforts, vigilance remains critical. The *2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain* promotes: prioritizing non-opioid therapies; using the lowest effective dose for the shortest duration; regular monitoring; and providing access to take-home naloxone.

**2019 Recall:** In April 2019, specific lots of Hydromorph Contin 24mg capsules were voluntarily recalled by Purdue Pharma because affected lots may have contained hydromorphone levels that did not conform to label declaration . This underscores the importance of verifying current product information.

### PATIENT MEDICATION INFORMATION FOR HYDROMORPH CONTIN 24MG

Read the patient information leaflet supplied with your prescription. Key instructions include:

– Take exactly as directed by your healthcare professional – every 12 hours .
– Swallow capsules whole or sprinkle contents on applesauce/custard and swallow immediately without chewing .
– Do not share or sell the medication.
– Avoid driving or operating machinery until you understand how it affects you .
– Report any side effects promptly.

### STORAGE, HANDLING, AND DISPOSAL OF HYDROMORPH CONTIN 24MG CANADA

Store capsules at room temperature, protected from light, in the original child-resistant packaging . Keep locked away and out of sight/reach of children and pets . Dispose of unused or expired capsules through pharmacy take-back programs or authorized collection sites.

### FREQUENTLY ASKED QUESTIONS ABOUT HYDROMORPH CONTIN 24MG CANADA

**Can I open the capsule and sprinkle it on food?** Yes, you can open the capsule and sprinkle the contents on a tablespoon of applesauce or custard. Swallow immediately without chewing and rinse your mouth with water afterwards. Do not keep any mixture for another dose .

**Can I drive while taking Hydromorph Contin 24mg?** It is not recommended until you know how the medication affects your alertness and coordination, as it can cause significant drowsiness and impair judgment .

**What should I do if I miss a dose?** Take it as soon as you remember, unless it is nearly time for the next scheduled dose. Do not double the dose. Consult your pharmacist or doctor for guidance.

**Is Hydromorph Contin available in other strengths?** Yes. Hydromorph Contin is available in strengths of 3 mg, 4.5 mg, 6 mg, 9 mg, 10 mg, 12 mg, 18 mg, 20 mg, 24 mg, and 30 mg .

### HISTORY AND MANUFACTURING OF HYDROMORPH CONTIN BY PURDUE PHARMA IN CANADA

Purdue Pharma has been a manufacturer of opioid analgesics in Canada for decades. Hydromorph Contin has been marketed in Canada since December 31, 1996 . The company’s production of controlled-release hydromorphone supports pain management options while adhering to Health Canada’s rigorous manufacturing and quality standards.

### THE CANADIAN REGULATORY FRAMEWORK FOR HYDROMORPH CONTIN 24MG

This product is regulated under the *Controlled Drugs and Substances Act* (CDSA) as a narcotic (CDSA I), the *Narcotic Control Regulations*, and the *Food and Drugs Act* . A Canadian Specific Opioid targeted Risk Management Plan (CSO-tRMP) has been submitted for this product, which includes Healthcare Professional Education materials and a Drug Utilisation Study (DUS) . Prescribing, dispensing, record-keeping, and monitoring follow both federal and provincial requirements.

### SUPPORT RESOURCES FOR CANADIAN PATIENTS AND CAREGIVERS

– Provincial pain clinics and palliative care services.
– Addiction and mental health support programs.
– Public naloxone distribution initiatives.
– Health Canada and provincial ministry resources for safe medication use.
– Health Canada’s Canada Vigilance Program for reporting side effects.

—

**DISCLAIMER:** This article is for informational and educational purposes only and is not medical advice. Hydromorphone is a potent Schedule I controlled narcotic available in Canada only by prescription. All use must be supervised by a licensed Canadian healthcare professional. Misuse or improper use can cause addiction, life-threatening respiratory depression, overdose, and death. In an emergency, call 911 or your provincial poison control centre immediately. Always verify the latest information on the Health Canada Drug Product Database and consult your healthcare team for personalized advice.

### CONCLUSION: RESPONSIBLE USE OF HYDROMORPH CONTIN 24MG IN CANADA

When prescribed and used appropriately under medical supervision in accordance with Health Canada standards and Canadian guidelines, Hydromorph Contin 24mg 12h-capsule can provide important long-term pain relief for patients requiring continuous opioid therapy. Patient safety, informed consent, adherence to directions, and collaboration with your healthcare team are essential. Prioritize non-opioid options whenever possible and utilize available support resources.

**DISCLAIMER:** This article is for informational and educational purposes only and does not constitute medical advice. Hydromorph Contin 24mg 12h-capsule is a prescription-only Schedule I controlled narcotic under the *Controlled Drugs and Substances Act* in Canada, manufactured by Purdue Pharma. It is authorized by Health Canada for the management of moderate to severe pain in adults when non-opioid alternatives are inadequate. Always consult your licensed Canadian healthcare professional before starting, adjusting, or stopping this medication. Individual responses vary. Always verify the most current product information on the Health Canada Drug Product Database.

—

**Hydromorph Contin 24mg 12h-capsule Canada** is a controlled-release opioid analgesic produced by Purdue Pharma, a pharmaceutical company based in Toronto, Ontario . Marketed since 1996, this product meets stringent Health Canada standards for quality, safety, and efficacy . The 24 mg strength is supplied as a sustained-release capsule containing 24 mg of hydromorphone hydrochloride as the active ingredient . The capsule shell contains black iron oxide as a distinguishing colorant .